Immunotherapy is a type of cancer treatment that helps the body's own immune system find and attack cancer cells. For mesothelioma, the most common form uses drugs called checkpoint inhibitors, which release natural brakes on immune cells so they can recognize the tumor. It's given through an IV and is used for some patients whose cancer can't be removed with surgery.
Origin
From the Latin immunis, "exempt," and the Greek therapeia, "healing." Modern cancer immunotherapy grew out of decades of tumor-immunology research, and checkpoint inhibitors reached wide use in the 2010s. A combination of two such drugs was approved for pleural mesothelioma in 2020.
Significance in Asbestos Context
For mesothelioma patients, immunotherapy became a major option after a 2020 trial showed that combining nivolumab and ipilimumab helped some people with pleural mesothelioma live longer than chemotherapy alone, especially those with the non-epithelioid (sarcomatoid or biphasic) subtypes. It doesn't work for everyone, and it can cause the immune system to attack healthy organs, so patients are watched for side effects affecting the skin, gut, lungs, and glands. Ask your oncologist whether immunotherapy fits your cell type and overall health, and whether a clinical trial combining it with other treatments is available. Records of the treatments you received and how you responded can matter to both your care and a claim.
Example Sentence
After surgery wasn't an option, his oncologist started him on immunotherapy using a combination of two checkpoint inhibitors.
Related Terms
Checkpoint Inhibitor, Chemotherapy, Targeted Therapy, Clinical Trial, Epithelioid Mesothelioma, Sarcomatoid Mesothelioma
Notes
- Ask whether your mesothelioma subtype (epithelioid, sarcomatoid, or biphasic) affects how well immunotherapy is likely to work.
- Report new symptoms promptly, since immune-related side effects can develop quickly and are treatable if caught early.
- Keep a record of every drug, dose, and response; treatment records support both ongoing care and any claim.
In the research library
559 studies in our medical research library mention Immunotherapy in the title or abstract. Among the most cited:
- Mesothelin Immunotherapy for Cancer: Ready for Prime Time?R. Hassan, A. Thomas, C. Alewine, et al, 2016 · Journal of Clinical Oncology · cited 293 times
- COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC functionJ.D. Veltman, M.E. Lambers, M. van Nimwegen, et al, 2010 · BMC Cancer · cited 241 times
- Discovery of mesothelin and exploiting it as a target for immunotherapyI. Pastan, R. Hassan, 2014 · Cancer Research · cited 217 times
- Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumorsG. Espinosa-Carrasco, E. Chiu, A. Scrivo, et al, 2024 · Cancer Cell · cited 184 times
- CCL2 blockade augments cancer immunotherapyZ.G. Fridlender, G. Buchlis, V. Kapoor, et al, 2010 · Cancer Research · cited 162 times
The journals that publish most on it: Cancers (36), Frontiers in Oncology (23), Frontiers in Immunology (23).
Category: Treatments & Therapies · All Lexicon terms A–Z
This page is provided for general informational purposes and does not constitute legal advice. Every asbestos case turns on its own facts, exposure history, diagnosis, deadlines, available evidence, and applicable law. Reviewing this page does not create an attorney-client relationship. For advice about your specific situation, call 833-4-ASBESTOS for a free case review.